LORA MAY VAVERKA
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family ENID, OK NPI 1124036744
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family OK Janssen Biotech, Inc. All categories
General Payments — all program years on this page
$1,714.10
- Category: General Payments
- Program years: PY2021–2024
- Record count: 62
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,670.03 across 60 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,496.04 | 58 |
| Education | $173.99 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $242.45 | 8 |
| Acerta Pharma LLC | $161.92 | 5 |
| Gilead Sciences, Inc. | $139.96 | 4 |
| Regeneron Healthcare Solutions, Inc. | $135.17 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $117.47 | 5 |
| Takeda Pharmaceuticals U.S.A., Inc. | $97.43 | 1 |
| PFIZER INC. | $88.62 | 6 |
| ABBVIE INC. | $87.95 | 1 |
| Pharmacosmos Therapeutics Inc. | $72.42 | 2 |
| Merck Sharp & Dohme Corporation | $70.37 | 4 |
| SOBI, INC | $56.24 | 3 |
| Rigel Pharmaceuticals, Inc. | $54.48 | 3 |
| PUMA BIOTECHNOLOGY, INC. | $48.82 | 2 |
| ARRAY BIOPHARMA INC | $48.08 | 2 |
| Incyte Corporation | $45.36 | 2 |
| Genentech USA, Inc. | $40.11 | 2 |
| Mirati Therapeutics, Inc. | $24.56 | 1 |
| Astellas Pharma US Inc | $23.71 | 1 |
| Celgene Corporation | $22.98 | 1 |
| EISAI INC. | $21.32 | 1 |
| Daiichi Sankyo Inc. | $20.83 | 1 |
| Alexion Pharmaceuticals, Inc. | $19.25 | 1 |
| ADC Therapeutics America, Inc. | $15.82 | 1 |
| Karyopharm Therapeutics Inc. | $14.71 | 1 |
By program year
Records — PY2024 (60)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.